Nature Medicine, Published online: 13 March 2025; doi:10.1038/s41591-025-03600-2
In a large-scale, international, multicenter, phase 1/1b trial, treatment of patients with advanced solid tumors with the B7H3-targeting antibody–drug conjugate YL201 was safe and showed preliminary clinical efficacy.
